跳至主要内容
临床试验/NCT00849966
NCT00849966已完成2 期

Celecoxib for Pediatric Adenotonsillectomy: A Randomized Controlled Double Blinded Study

Children's Hospital of Eastern Ontario1 个研究点 分布在 1 个国家目标入组 282 人开始时间: 2009年8月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
282
试验地点
1
主要终点
The investigators primary objective will be to determine the level of postoperative pain relief celecoxib provides for children within the first three days after undergoing tonsillectomy, or adenotonsillectomy

研究概览

简要总结

The investigators' study will involve the administration of either placebo or celecoxib to children aged 2 to 18 years of age undergoing tonsillectomy and assessing pain relief, impact on quality of life and side effect profile.

详细描述

The study will consist of two arms, one placebo and the other celecoxib. To establish baseline data on the day of surgery the parents will be required to complete a validated parent report quality of life inventory, multi-dimension fatigue scale and pediatric pain questionnaire for the preceding week. Children/adolescents aged 8 to 18 years of age will be required to complete a child self-report of the same modules. Children undergoing adenotonsillectomy will receive either placebo or celecoxib by mouth one hour prior to their surgery. They will all receive preoperative acetaminophen. Premedication with midazolam will be at the discretion of the attending anesthesiologist. The patients will undergo a standardized anesthetic protocol including postoperative management of pain and nausea and vomiting. The patients, while under anesthesia, will have blood drawn to screen for occult liver and kidney disease, determine their CYP2C9 genotype and reserve for future gene chip micro array analysis.

Patients in both study arms will receive a second dose of celecoxib or placebo by mouth in the evening after surgery and then consecutively in the morning and evening for 72 hours. For seven days after the surgery the families will record once a day pain scores, document analgesic use and any side effects or adverse events. The families will be contacted by phone in the evening of the first three postoperative days to ensure that they understand and are completing the required documentation. On the seventh postoperative day the parents and children aged 8 to 18 years of age will be contacted by phone and instructed to complete the same two validated questionnaires concerning quality of life and level of fatigue completed on the day of surgery. Parents of children less than eight years of age will be responsible for completing these questionnaires based on observations of their children. On the 11th postoperative day the families will be contacted by e-mail or regular mail to complete a questionnaire asking about the extent of contact with the healthcare system, bleeding complications, recovery and overall satisfaction with their care.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
2 Years 至 18 Years(Child, Adult)
性别
All
接受健康志愿者

入选标准

  • Children aged 2-18 years
  • Tonsillectomy, or adenotonsillectomy
  • No exclusion criteria

排除标准

  • Age < 2yrs and >18yrs old
  • BMI < 10th or > 95th percentile
  • Serum creatinine (Cr) > 2 X UNL (upper normal limit)
  • Abnormal liver function; namely alanine aminotransferase (ALT) > 1.5 X UNL, alkaline phosphatase (ALP) > 5X UNL, total bilirubin > 2 X UNL
  • History of peptic ulcer disease.
  • History of bleeding disorders
  • History of severe asthma (requiring recent hospital admission or oral corticosteroid therapy)
  • Allergy to celecoxib, sulfonamide compounds or NSAIDs
  • Patients receiving CYP2C9 inhibitors fluconazole, amiodarone and oxandrolone
  • Patients receiving CYP2C9 inducers rifampin and phenobarbital
  • Extremes of body mass index (BMI) (age related below10th or above 90th percentile)
  • Parents of any participants, irrespective of age, who are unable to read and understand instructions relayed in English or French
  • Participant and/or parents of any participants, irrespective of age, who suffer from dementia, psychosis, significant developmental delay or other impairment that would prohibit the understanding and giving of informed consent or assent or the participation in self-care or toxicity reporting

研究组 & 干预措施

A

Experimental

Celebrex suspension

干预措施: Celebrex suspension (Drug)

B

Placebo Comparator

Placebo

干预措施: Celebrex suspension (Drug)

B

Placebo Comparator

Placebo

干预措施: Placebo (Drug)

结局指标

主要结局

The investigators primary objective will be to determine the level of postoperative pain relief celecoxib provides for children within the first three days after undergoing tonsillectomy, or adenotonsillectomy

时间窗: three days

次要结局

  • To measure the frequency of adverse events post surgery(For seven days immediately after the procedure)
  • To quantify the impact of celecoxib on fatigue(Day 0 before the procedure and again on Day 7 afterwards)
  • To quantify the impact of celecoxib on quality of life(Day 0 before the procedure and again on Day 7 afterwards)
  • To quantify the impact of celecoxib on pain relief postsurgery(Day 0 before the procedure and every day until Day 7 afterwards)
  • To identify polymorphisms of CYP2C9 genotypes and their impact on pain relief.(Sample taken during the procedure)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Kimmo Murto

Deputy Academic Chief

Children's Hospital of Eastern Ontario

研究点 (1)

Loading locations...

相似试验